2015 Agenda

Plenary
Therapeutic Sessions
Workshops
Showcase
 

Tuesday, December 1, 2015

7:45am-5:30pm Registration
7:45am-8:45am Pipeline Café
8:45am Welcoming Remarks
9:00am-10:00am

Opening Plenary Session: Looking for Innovation In the Academic Haystack

Moving important therapies from the bench to the bedside is one of the major challenges that faces our industry year in and year out. Experienced leaders from academia, industry and government will look at translational medicine programs past and present and discuss how the stakeholders should best address this issue going forward.

Moderator: Mark Simon, Partner, Torreya Partners

  • Kurt W. Marek, PhD, Deputy Director (OTAC), National Heart, Lung & Blood Institute
  • Bernard Munos, MS, MBA, Senior Fellow, FasterCures
  • Carlo Rizzuto, PhD,CEO, Highline Therapeutics, Inc., Venture Partner, Versant Ventures
  • Reginald Seeto, MD, Vice President, Head of Partnering & Strategy, AstraZeneca/Medimmune
10:00am-11:00am

Brain Disease Breakthroughs – Are We at the Tipping Point?

Over the last five years the number of drugs being developed for brain and nervous system disorders fell 50% to a dismal 129 as many pharma companies abandoned the pursuit of new brain disease therapies. But recent scientific advances may have turned the tide. Last year investors poured $3.3 billion into companies that are developing drugs for neurodegenerative and psychiatric illnesses. From immunotherapy to gene therapy, and everything in between, which approaches are showing the greatest promise for the treatment of such diseases as depression, Parkinson’s Disease, Alzheimer’s Disease and Multiple Sclerosis?

Moderator: Ginger S. Johnson, PhD, Vice President, Defined Health

  • Ashish Dugar, PhD, MBA, Vice President, Commercial Development, Intra-Cellular Therapies, Inc.
  • Todd T. Sherer, PhD, Chief Executive Officer, Michael J. Fox Foundation for Parkinson’s Research
  • Carlo Rizzuto, PhD,CEO, Highline Therapeutics, Inc., Venture Partner, Versant Ventures
  • Eric Siemers, MD, Medical Director, Alzheimer’s Disease Team, Eli Lilly and Company
  • Stacie Weninger, PhD, Executive Director, F-Prime Capital Partners
10:00am-11:00am

Summit Showcase

10:00am-12:00pm

Partnering Forum

11:00am-12:00pm

Workshop:
Key Indicators That It’s The Right Time to Look For A Strategic Partner

For an emerging company, it is often challenging to know when it is time to start looking for a strategic partner. There are many factors to consider – stage of development of a lead asset, intellectual property, management experience, corporate strategy and target market among them. Partnering your assets too soon is like leaving money on the table, but waiting too long can hinder your ability to meet key milestones. This panel will discuss how you will know when it’s the right time to come to the table.

Moderator: Lesley Stolz, PhD, Transactions Team, California Innovation Center, Johnson & Johnson Innovation

  • Nagesh Mahanthappa, PhD, MBA, CEO & President, Scholar Rock
  • Bill Newell, CEO, Sutro Biopharma, Inc.
  • Ronit Phail, Senior Director, Search & Evaluation, Corporate Business Development, Eli Lilly and Company
  • Amy Schulman, Venture Partner, Polaris Partners
11:00am-12:00pm

Summit Showcase

12:00pm-1:15pm Lunch with The Experts
12:00pm-1:15pm Pipeline Café
1:15pm-2:15pm

Immuno-oncology & Precision Medicine: The Double Whammy in Cancer Therapies

While immuno-oncology has been hailed as one of the top three cancer therapeutic advances of all time, many believe the greatest benefit will be realized by combining new immunotherapies with drugs that target the pathways that drive cancer cell growth. Join our panelists as they discuss what these combined therapeutic approaches mean to patients, the pharma industry, and the emerging companies working to bring new cancer therapies into clinical development.

Moderator: Janet L. Dally, Founder, Maidstone Life Sciences

  • Sharon Benzeno, PhD, MBA, Senior Director of New Product Development, Adaptive Biotechnologies Corp.
  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Ramesh Kumar, PhD, President & CEO, Onconova Therapeutics
  • Daniel Teper, PharmD, Chief Executive Officer, Immune Pharmaceuticals
  • Nicholas Wilson, PhD, Senior Director, Cancer Immunology, Agenus Inc..
1:15pm-2:00pm

Summit Showcase

1:15pm-3:15pm

Partnering Forum

2:15pm-3:15pm

Workshop:
Growing Your Company: Assembling the External Team That Will Take You Forward

There comes a time when management of an emerging life science company needs to reach beyond their internal team and build their external team to continue their progress toward getting an asset approved. From financial advisers to regulatory consultants, legal advisors and communications specialists, assembling the right team can be daunting. This panel will cover some of the basics about identifying when and which external advisors you need and how you should identify who will be the right fit.

Moderator: Claudia Hirawat, President, PTC Therapeutics, Inc. (retired)

  • Laurence Blumberg MD, President and Chief Executive Officer, Syntimmune Inc
  • Peter DeLuca, Partner, Carter, DeLuca, Farrell & Schmidt, LLP
  • Kristen C. Kosofsky, enior Managing Director for Life Sciences, Hercules Technology Growth Capital
  • Steven Kreit, Partner, EisnerAmper
  • Jules T. Mitchel, MBA, PhD, President, Target Health, Inc.
2:15pm-3:30pm

Summit Showcase

3:15pm-3:30pm Break
3:30pm-4:30pm

Workshop:
Contracts Are Forever: Positioning Your Assets

You’ve finally got the right partner, the right development commitment and the right terms. Negotiating the nitty-gritty of a contract may seem like an after-thought. But the small details in a contract can have big effects down the line. This panel will cover how to position your asset in a contract as well as the road-bumps and land-mines that have tripped up other companies that you need to be aware of so you won’t regret the contract in the morning.

Moderator: Brian P. O’Shaughnessy, Shareholder, RatnerPrestia, and Public Policy & Regional Vice President, Licensing Executives Society (LES)

  • Vincent Andrews, Associate General Counsel, Eisai, Inc.
  • Pamela R. Demain, Executive Director, Transactions, Business Development & Licensing, Merck & Co., Inc.­­­
  • Ann Kraft, Executive Director, Licensing & Business Development, Purdue Pharma LP
  • Eric Victory, Vice President & Head for Cardiovascular & Metabolic Disease, Partnering & Strategy, MedImmune
3:30pm-4:15pm Partnering Forum
3:30pm-4:30pm

Summit Showcase

4:30pm-5:30pm

Plenary Session: Understanding How Potential Partners & Investors Look at Valuation of Early Stage Assets

Placing a value on assets you have spent years developing is a difficult task for the innovator-entrepreneur. But ultimately the value of any asset is the price a partner or investor is willing to pay for it. This panel will discuss how ‘buyers’ approach establishing a value for early stage assets and provide valuable insight into what the guy across the table is thinking.

Moderator: Ellen B. Corenswet, Partner, Covington & Burling

  • Michael Gutch, PhD, Executive Director – Corporate Development, AstraZeneca
  • Marian T. Nakada, PhD, Vice President Venture Investments, Johnson & Johnson Development Corp.
  • Art Pappas, Managing Partner, Pappas Ventures
  • Dennis J. Purcell, Managing Partner, Aisling Capital LLC
  • Alex Zisson, Partner, Thomas, McNerney & Partners LLC
5:30pm-7:00pm Reception & Pipeline Café

Wednesday, December 2, 2015

8:00am-3:00pm Registration
8:00am-9:00am Pipeline Café
9:00am-10:00am

Plenary Session: The Early Stage Funding Ecosystem – Angels, VCs, Family Offices, Government, MRFs, and Others

In the midst of the hype about a biotech investment bubble it can be easy to forget that funding for early stage companies is still hard to come by – unless you are an early stage company. In the aftermath of the financial crisis new investment options emerged including angel networks, family offices and medical research foundations. Now that the market has recovered, these new players continue to provide crucial funding for early stage biotechs. This panel will discuss the evolution of the financing ecosystem and how to access it.

Moderator: Joseph V. Gulfo, MD, MBA, Rothman Institute of Innovation & Entrepreneurship, Fairleigh Dickinson University

  • Inna Grodzovski, PhD, Senior Analyst, FreeMind Group
  • Kimberly Ha, Senior Director, FTI Consulting
  • William S. Podd, President and Executive Director, Landmark Angels, Inc.
  • Barbara S. Schilberg, Managing Director and Chief Executive Officer, BioAdvance Ventures
  • Peter Young, Executive-in-Residence, A.M. Pappas & Associates
10:00am-11:00am

Metabolic Disease: Personal Choice or Destiny?

More than one quarter of the world’s adults are living with so called “Life Style” diseases such as obesity, type II diabetes, cardiovascular disease and fatty liver disease. While numerous drugs currently exist to treat diabetes and cardiovascular issues, the demand for them continues as our aging and increasingly obese population fuels market demand. Obesity, fatty liver disease (steatosis), and its more severe form: NASH (non-alcoholic steatohepatitis), have been more challenging targets for drug development. What approaches are showing the most promise for the development of new therapies and where are the breakthroughs occurring? Key Leaders will discuss these issues and provide insights into our changing understanding of the underlying biology and the business forces that will inform future development.

Moderator: Stephen D. Wolpe, PhD, Entrepreneur-in-Residence, BioHealth Innovation

  • Ethel Rubin, PhD, Entrepreneur In Residence/Med Tech Investments & New Ventures, BioHealth Innovation
  • Lauren P. Shearman, PhD, Executive Director, Search & Evaluation Lead, Cardiometabolic Diseases, Business Development & Licensing, Merck & Co. Inc.
  • Eric Victory, Vice President & Head for Cardiovascular & Metabolic Disease, Partnering & Strategy, MedImmune
  • Chris Vlahos, PhD, Director Global External R&D, Eli Lilly and Company
10:00am-11:00am

Summit Showcase

10:00am-12:00pm

Partnering Forum

11:00am-12:00pm

Workshop:
IP – A Pillar of Valuation

When it comes to determining value of an asset, the strength of the intellectual property that backs it up is one of the most important considerations. This workshop will discuss key issues about how the state of the underlying IP drives value.

Moderator: Deborah A. Somerville, Partner, Kenyon & Kenyon LLP

  • Kathleen A. Denis, PhD, Associate Vice President, Technology Transfer, The Rockefeller University
  • Thomas Gallagher, Senior Vice President, Intellectual Property, Kadmon Corporation
  • A. Antony Pfeffer, Partner, Kenyon & Kenyon
  • Lesley Stolz, PhD, Transactions Team, California Innovation Center, Johnson & Johnson Innovation
11:00am-12:00pm

Summit Showcase

12:00pm-1:15 pm Lunch with the Experts
12:00pm-1:15pm Pipeline Café
1:15pm-2:15pm

Summit Showcase

1:15pm-2:30pm Strategic Partner Showcase
1:15pm-3:15pm Partnering Forum
2:15pm-3:15pm

Workshop:
Communications: Why Getting Your Elevator Pitch Right Is So Important, Yet So Difficult

It’s obvious to you why your technology and/or your company deserves funding, but it’s not obvious to everyone else. This workshop will discuss how best to translate your years of work into a ten-second elevator pitch that will impress investors. Getting your story down to a compelling pitch is one of the most difficult tasks that a management team has to undertake and it is often overlooked. This panel will discuss how to express your story and winnow it down to effectively communicate your company value.

Moderator: Gregory Q. Tiberend, President & CEO, Tiberend Strategic Advisors, Inc.

  • Kate de Santis, Vice President of Investor Relations, Iroko Pharmaceuticals, LLC
  • Anna Kazanchyan, MD, Senior Vice President, Business Development, Ovid Therapeutics Inc.
  • Felicia Vonella, Director, Investor Relations & Corporate Communications, Acorda Therapeutics
2:15pm-3:30pm

Summit Showcase

3:15pm-3:30pm Break
3:30pm-4:30pm

Summit Showcase

3:30pm-4:15pm Strategic Partner Showcase
3:30pm-4:15pm Partnering Forum
4:30pm-5:30pm

Plenary Session & Closing Reception: Pharma & Big Bio’s Appetite for Early Innovation

Pharmaceutical, and increasingly Big Bio, companies regularly look outside their organizations for innovation, but what are they looking for and where are they looking? This panel of biopharma industry veterans will discuss how they approach accessing early stage innovation and how a scientific innovator can position their technology to attract the attention of a buyer.

Moderator: Tim Opler, Partner, Torreya Partners

  • Karen Akinsanya, Head, Early Stage Assessment, Merck
  • Jarrod Borkat , Head, External Collaborations and Biotech Hubs, MedImmune
  • Andrew Hass, Senior Advisor, Oncology Search & Evaluation, Eli Lilly and Company
  • Nouhad Husseini, Senior Director, Business Development, Regeneron Pharmaceuticals
  • Jeremy Springhorn, PhD, Partner, Flagship Ventures

 

Plenary
KOLs
Workshops
Showcase